Scribe Therapeutics, a Phase 1 biotech developing CRISPR genetic therapies for high cholesterol, announced terms for its IPO on Monday.
The Alameda, CA-based company plans to raise $100 million by offering 7.2 million shares at a price range of $13 to $15. Existing shareholder Eli Lilly intends to purchase shares in the offering that together with its existing holdings would result in a post-IPO stake of 10.9%. The company also plans to raise an additional $7.5 million in a concurrent private placement to Sanofi. At the midpoint of the proposed range, Scribe Therapeutics would command a fully diluted market value of $235 million.
Scribe Therapeutics is developing in vivo CRISPR-based therapies aimed at extending healthy lifespan through disease prevention, with an initial focus on cardiovascular and metabolic disease. Its lead candidate, STX-1150, uses an epigenetic silencing approach to durably lower LDL-C by repressing PCSK9 expression, without permanently altering DNA. It's currently in a first-in-human trial in Australia under TGA clearance, with initial data expected in the first half of 2027. Two follow-on programs, STX-1200 and STX-1400, apply the company's XE gene-editing technology to target Lp(a) and triglycerides as additional drivers of atherosclerotic cardiovascular disease, and are supported in part by CIRM grant funding, with Phase 1 trials anticipated in 2027 and 2028.
Scribe Therapeutics was founded in 2017 and booked $36 million in collaboration revenue for the 12 months ended March 31, 2026. It plans to list on the Nasdaq under the symbol SCTX. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are the joint bookrunners on the deal. It is expected to price during the week of July 20, 2026.
